Nanospectra Biosciences Announces University of Texas Medical Branch at Galveston as Clinical Trial Site
HOUSTON, TX – March 27, 2019 – Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, announced today the addition of University of Texas Medical Branch (UTMB) at Galveston as the fifth trial site in its pilot feasibility study “MRI/US Fusion Imaging and Biopsy in Combination with Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue” (NCT02680535).
Prostate cancer remains the most frequent non-skin cancer in men. Over 160,000 men in the United States are diagnosed with prostate cancer annually, with approximately 90 percent having localized disease. However, over 100,000 U.S. men with low to intermediate-risk prostate cancer undergo surgery or radiation each year, resulting in significant and unnecessary side effects including incontinence and erectile dysfunction.
“We are excited to include UTMB in our line-up of top-tier research sites evaluating the use of AuroLaseÆ,” said David Jorden, CEO of Nanospectra. “As the first ultra-focal therapy for the ablation of prostate cancer tissue, AuroLase has the potential to return patients to their normal lifestyle more quickly and with significantly fewer side effects than surgery, radiation or traditional focal therapies.”
Stephen B. Williams, M.D., Chief of Urology, Associate Professor, Director of Urologic Oncology, and Director Urologic Research is the lead trial investigator at UTMB, Galveston. “This is an exciting new organ-sparing technology for prostate cancer patients that helps to preserve quality of life and hopefully provide durable oncologic results,” said Dr. Williams. “And for the first time ever using targeted thermal ablation therapy, urologists have the ability to diagnose, treat and follow-up with their patients; further extending the continuity of care.”
The trial, which is designed to demonstrate the safety and efficacy of AuroLase Therapy in the focal ablation of neoplastic prostate tissue via nanoparticle-directed irradiation, has enrolled thirty-nine (39) subjects to date at Mount Sinai New York, University of Michigan, and University of Texas Health Science Center in Houston. In addition, Johns Hopkins University has received institutional review board (IRB) clearance to begin enrolling and treating patients for the trial. Efficacy of focal ablation will be assessed at three and twelve months after treatment. Assuming demonstration of efficacy and procedural optimization, the trial will progress to a pivotal study.
Click here for clinical trial information at University of Texas Medical Branch, Galveston.
About Nanospectra Biosciences
Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase®, the company’s lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra’s ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.
For more information visit https://www.nanospectra.com.